Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

AXLA | Axcella Health Inc

Index	-	P/E	-	EPS (ttm)	-19.14	Insider Own	63.89%	Shs Outstand	2.95M	Perf Week	0.87%
Market Cap	30.80M	Forward P/E	-	EPS next Y	-4.75	Insider Trans	0.00%	Shs Float	1.06M	Perf Month	9.49%
Income	-48.23M	PEG	-	EPS next Q	-1.25	Inst Own	7.02%	Short Float / Ratio	22.72% / 0.26	Perf Quarter	91.30%
Sales	0.00M	P/S	-	EPS this Y	87.25%	Inst Trans	-	Short Interest	0.24M	Perf Half Y	-16.51%
Book/sh	-0.77	P/B	-	EPS next Y	0.00%	ROA	-162.77%	Target Price	-	Perf Year	-75.86%
Cash/sh	3.01	P/C	3.47	EPS next 5Y	0.00%	ROE	-1370.17%	52W Range	2.59 - 49.25	Perf YTD	27.51%
Dividend	-	P/FCF	-	EPS past 5Y	-2.50%	ROI	-	52W High	-78.80%	Beta	0.93
Dividend %	-	Quick Ratio	0.80	Sales past 5Y	0.00%	Gross Margin	-	52W Low	303.48%	ATR	4.57
Employees	11	Current Ratio	0.80	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	48.69	Volatility	30.98% 49.35%
Optionable	No	Debt/Eq	-	EPS Q/Q	88.56%	Profit Margin	-	Rel Volume	0.86	Prev Close	10.57
Shortable	No	LT Debt/Eq	-	Earnings	Aug 03 BMO	Payout	-	Avg Volume	930.17K	Price	10.44
Recom	-	SMA20	-26.22%	SMA50	23.06%	SMA200	1.86%	Volume	799,001	Change	-1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-12-21	Initiated	Noble Capital Markets	Outperform	$6
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$9 → $5
Jul-30-21	Downgrade	JP Morgan	Neutral → Underweight
Jul-06-21	Initiated	H.C. Wainwright	Buy	$14
Jun-03-21	Resumed	Chardan Capital Markets	Buy	$10 → $16
Nov-18-20	Initiated	ROTH Capital	Buy	$28
Oct-27-20	Initiated	Chardan Capital Markets	Buy	$16
Sep-25-20	Initiated	B. Riley FBR	Buy	$14
Jul-31-20	Initiated	Piper Sandler	Overweight	$25
May-28-20	Initiated	Wedbush	Outperform	$28
May-01-20	Initiated	BTIG Research	Buy	$10
Jun-03-19	Initiated	SVB Leerink	Outperform	$21
Jun-03-19	Initiated	JP Morgan	Overweight	$20
Jun-03-19	Initiated	Goldman	Buy	$25

Show Previous Ratings

Sep-20-23 11:28AM	Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now (InvestorPlace) -14.73%
Sep-15-23 09:40AM	Are Medical Stocks Lagging Axcella Health (AXLA) This Year? (Zacks) -38.23%
Sep-14-23 04:30PM	Axcella Announces Reverse Stock Split Effective September 19, 2023 (Business Wire) -15.13%
Aug-30-23 09:40AM	Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year? (Zacks) -15.24%
09:15AM	Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug (Zacks)
08:00AM	Loading…
Aug-29-23 08:00AM	Axcella Granted Patent for Long COVID Fatigue Treatment (Business Wire) +298.94%
Aug-03-23 07:30AM	Axcella Reports Second Quarter Financial Results and Provides Business Update (Business Wire)
May-04-23 04:30PM	Axcella Reports First Quarter Financial Results and Provides Business Update (Business Wire) +6.33%
Apr-17-23 08:00AM	Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023 (Business Wire) -6.91%
Apr-14-23 12:01PM	Big Bank's Big Q1 Performance, Florida Gov. Quietly Slips 6-Week Abortion Ban Into Law, Subway Sandwich Seeks $10B Sale: Today's Top Stories (Benzinga)
11:39AM	Long COVID-Fatigue Impacts 50M People - Axcella Health Seeks Funding To Support Drug Development (Benzinga)
Mar-30-23 08:00AM	Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (Business Wire) +15.52%
Feb-15-23 04:10PM	Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue (Business Wire) -5.53%
Feb-09-23 04:45PM	Axcella Therapeutics to Participate in the SVB Securities 2023 Global Biopharma Conference (Business Wire)
Jan-25-23 10:53AM	Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More (Zacks)
05:34AM	Loading…
05:34AM	With lean staff, low cash, Axcella races ahead with Long Covid drug (American City Business Journals)
Jan-24-23 09:50AM	Benzinga's Talk of the Town: Top Social Trending Stories You Need To Know (Benzinga) +39.53%
06:43AM	Why Are Axcella Health Shares Gaining Today? (Benzinga)
Jan-23-23 04:15PM	Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue (Business Wire)
Dec-15-22 08:04AM	Axcella Therapeutics Puts Development Of NASH Program Aside, Reduces Workforce By 85% (Benzinga) -50.78%
Dec-14-22 08:01PM	Axcella Announces Program Reprioritization and Corporate Restructuring (Business Wire)
Dec-08-22 10:00AM	Great news for Axcella Health Inc. (NASDAQ:AXLA): Insiders acquired stock in large numbers last year (Simply Wall St.)
Nov-11-22 09:35AM	Axcella Health Inc. (AXLA) Loses 47.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +11.79%
Nov-03-22 09:59AM	Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (Business Wire) -12.62%
Nov-01-22 07:00AM	Axcella Reports Third Quarter Financial Results and Provides Business Update (Business Wire) -7.92%
Oct-27-22 08:30AM	Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022 (Business Wire)
Oct-14-22 01:24PM	Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference (Business Wire) +10.49%
Oct-13-22 08:00AM	Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members (Business Wire)
Sep-29-22 09:17AM	Axcella Shares Jump Despite Mixed Bag Data From Mid-Stage NASH Trial (Benzinga) +11.56%
06:00AM	Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) (Business Wire)
08:40AM	Loading…
Sep-17-22 08:40AM	Institutions profited after Axcella Health Inc.'s (NASDAQ:AXLA) market cap rose US$35m last week butprivate equity firms profited the most (Simply Wall St.)
Sep-12-22 08:00AM	Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (Business Wire) +9.14%
Aug-12-22 08:30AM	Edited Transcript of AXLA.OQ earnings conference call or presentation 12-Aug-22 12:30pm GMT (Thomson Reuters StreetEvents)
07:30AM	Axcella Reports Second Quarter Financial Results and Provides Business Update (Business Wire)
Aug-10-22 08:19AM	The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics (Zacks)
Aug-09-22 07:40AM	5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates (Zacks)
Aug-04-22 05:50AM	The Petri Dish: Axcella advances long Covid drug (American City Business Journals) +5.88%
Aug-02-22 06:34AM	Axcella's NASH Candidate Shows Favorable Action In Long COVID-Related Fatigue (Benzinga)
06:00AM	Axcella long COVID treatment helps some patients in small trial (Reuters)
06:00AM	Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID (Business Wire)
Jul-01-22 08:21AM	Great news for Axcella Health Inc. (NASDAQ:AXLA): Insiders acquired stock in large numbers last year (Simply Wall St.)
Jun-27-22 02:35PM	From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid (Investor's Business Daily)
May-27-22 10:20AM	Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program (Zacks)
May-26-22 07:00AM	Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio (Business Wire) +16.77%
May-19-22 08:00AM	Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (Business Wire) +6.25%
May-05-22 07:00AM	Axcella Reports First Quarter Financial Results and Provides Business Update (Business Wire)
Apr-28-22 10:24AM	Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-20-22 10:49AM	Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon (Zacks)
Apr-19-22 11:02AM	TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down (Zacks)
Apr-18-22 11:26AM	Can Tenet Healthcare (THC) Post Q1 Earnings Beat on Low Costs? (Zacks)
Apr-12-22 10:49AM	Moderna (MRNA) Initiates Early-Stage Flu Vaccine Study (Zacks) -6.60%
Apr-07-22 02:50PM	Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study (Zacks)
02:32PM	Rhythm Pharmaceuticals (RYTM) Down Due to Study Design Changes (Zacks)
Apr-04-22 10:04AM	Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate (Zacks) +6.64%
09:40AM	Is Avanos Medical (AVNS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-30-22 07:32AM	Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (Business Wire)
Mar-23-22 07:02AM	Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022 (Business Wire)
Mar-17-22 12:36PM	What Type Of Shareholders Own The Most Number of Axcella Health Inc. (NASDAQ:AXLA) Shares? (Simply Wall St.) +22.44%
Mar-16-22 08:15AM	Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market (Business Wire) +7.33%
Mar-10-22 11:05AM	Here's Why You Should Retain Community Health (CYH) Stock (Zacks)
Mar-09-22 10:49AM	Anthem (ANTM) Rises 3.7% Since Q4 Earnings, Reiterates View (Zacks) +5.79%
Feb-28-22 09:00AM	Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs (PR Newswire)
Feb-15-22 10:05AM	INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT (PR Newswire) +6.59%
Feb-14-22 07:58AM	Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH (Business Wire)
Feb-10-22 07:30AM	Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference (Business Wire)
Feb-07-22 07:55AM	Axcella Therapeutics Announces Appointment of New Chief Financial Officer (Business Wire)
Jan-25-22 10:00AM	Axcella Health Inc. (AXLA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-13-22 12:08PM	Here's Why You Should Retain Cigna (CI) in Your Portfolio (Zacks)
Jan-06-22 07:58AM	Axcella Therapeutics Details Clinical and Operational Milestones for 2022 (Business Wire)
Jan-04-22 07:58AM	Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference (Business Wire)
Dec-31-21 10:05AM	Here's Why You Should Retain UnitedHealth Group (UNH) Now (Zacks)
Dec-30-21 10:00AM	Down 24% in 4 Weeks, Here's Why Axcella Health Inc. (AXLA) Looks Ripe for a Turnaround (Zacks)
Dec-16-21 12:41PM	Axcella Kickstarts Long COVID Phase 2 Clinical Trial (Benzinga)
07:28AM	Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial (Business Wire)
Dec-08-21 10:00AM	Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Axcella Health Inc. (AXLA) (Zacks) +7.32%
Dec-06-21 07:50AM	Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer (Business Wire)
Nov-18-21 07:58AM	Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference (Business Wire)
Nov-15-21 07:39AM	5 Winning Stocks Backed by the Overlooked Rising P/E Ratio (Zacks)
Nov-10-21 08:42AM	Is a Surprise Coming for Axcella Health (AXLA) This Earnings Season? (Zacks)
07:58AM	Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials (Business Wire)
Nov-02-21 07:58AM	Axcella Therapeutics Announces Upcoming Presentations at AASLDs The Liver Meeting® 2021 (Business Wire)
Oct-26-21 07:47PM	This Little Company Thinks It Can Beat Long Covid (Barrons.com) +28.93%
09:32AM	Axcella To Test NASH Candidate In Long COVID Patients (Benzinga)
07:00AM	Flagship Pioneering spinout thinks it has a treatment for 'long Covid' (American City Business Journals)
06:58AM	Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID (Business Wire)
Oct-19-21 07:58AM	Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021 (Business Wire)
Oct-13-21 10:00AM	Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change (PR Newswire)
Oct-05-21 07:58AM	Axcella Announces Upcoming Investor Conference Presentation (Business Wire)
Sep-28-21 10:57AM	Axcella's Leading Drug Candidate for Overt Hepatic Encephalopathy Offers Hope in a Market Requiring Innovation (Benzinga)
Sep-09-21 09:49AM	Axcella's First-of-Its-Kind NASH Treatment Shows Promising Early Results in Human Trials (Benzinga)
Sep-07-21 07:58AM	Axcella Announces Upcoming Investor Conference Presentation (Business Wire) -5.01%
Sep-02-21 06:43AM	What Is The Ownership Structure Like For Axcella Health Inc. (NASDAQ:AXLA)? (Simply Wall St.)
Aug-30-21 01:21PM	Breakthrough Multi-Targeted Drug Candidates Puts Axcella at Forefront of Liver Disease Treatment Market (Benzinga)
Aug-16-21 07:58AM	Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH (Business Wire)
Jul-29-21 07:28AM	Axcella Reports Second Quarter Financial Results and Provides Business Update (Business Wire)
Jul-22-21 07:28AM	Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021 (Business Wire)
Jun-30-21 07:28AM	Axcella Announces Initiation of EMMPOWER Phase 2 Clinical Trial of AXA1665 (Business Wire)
Jun-13-21 10:15AM	Axcella Accumulating Assets; Multiple Therapies in the Pipeline (TipRanks)
Jun-10-21 11:35AM	2 Strong Buy Penny Stocks That Could Rally to $10 (or More) (TipRanks) +48.70%
May-25-21 06:00AM	Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture (PR Newswire)

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Koziel Margaret	Chief Medical Officer	Mar 01	Sale	0.58	679	394	24,883	Mar 03 04:17 PM
Hinshaw William	President & CEO	Oct 19	Sale	1.56	16,000	25,027	82,012	Oct 19 06:49 PM
Flagship Ventures Fund IV Gene	10% Owner	Oct 13	Buy	1.64	10,383,760	17,029,366	14,101,638	Oct 17 04:42 PM
Societe des Produits Nestle S.	10% Owner	Oct 13	Buy	1.64	3,658,536	5,999,999	11,105,438	Oct 17 11:12 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AXLA | Axcella Health Inc

Upgrade your FINVIZ experience